BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 29908131)

  • 1. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T; Yamaga R; Fujita A; Itoh T
    J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Insufficiency in Concert with Renin-angiotensin-aldosterone Inhibition Is a Major Risk Factor for Hyperkalemia Associated with Low-dose Trimethoprim-sulfamethoxazole in Adults.
    Higashioka K; Niiro H; Yoshida K; Oryoji K; Kamada K; Mizuki S; Yokota E
    Intern Med; 2016; 55(5):467-71. PubMed ID: 26935365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
    Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients.
    Movilli E; Camerini C; Gaggia P; Zubani R; Cancarini G
    Am J Nephrol; 2018; 48(2):79-86. PubMed ID: 30071530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
    Maddirala S; Khan A; Vincent A; Lau K
    Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
    Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
    Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations.
    Mitterbauer C; Heinze G; Kainz A; Kramar R; Hörl WH; Oberbauer R
    Nephrol Dial Transplant; 2008 May; 23(5):1742-6. PubMed ID: 18234845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
    Beusekamp JC; Tromp J; van der Wal HH; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Rossignol P; Zannad F; Voors AA; van der Meer P
    Eur J Heart Fail; 2018 May; 20(5):923-930. PubMed ID: 29327797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study : ACEI/ARB and vascular calcification.
    Takaori K; Iwatani H; Yamato M; Ito T
    BMC Nephrol; 2021 Jan; 22(1):7. PubMed ID: 33407242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.
    Steely AM; Callas PW; Bertges DJ;
    J Vasc Surg; 2016 Mar; 63(3):715-21. PubMed ID: 26603543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Acute Kidney Disease after an Episode of AKI: A Multicenter Prospective Cohort Study.
    Hines A; Li X; Ortiz-Soriano V; Saleh S; Litteral J; Ruiz-Conejo M; Wald R; Silver SA; Neyra JA
    Am J Nephrol; 2020; 51(4):266-275. PubMed ID: 32088714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker.
    Jun HR; Kim H; Lee SH; Cho JH; Lee H; Yim HW; Yoon KH; Kim HS
    Cardiovasc Ther; 2021; 2021():5935149. PubMed ID: 33747123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction.
    Kane JA; Kim JK; Haidry SA; Salciccioli L; Lazar J
    Cardiology; 2017; 137(2):121-125. PubMed ID: 28376504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARγ agonists in uncomplicated diabetic patients.
    Raptis AE; Bacharaki D; Mazioti M; Marathias KP; Markakis KP; Raptis SA; Dimitriadis GD; Vlahakos DV
    Exp Clin Endocrinol Diabetes; 2012 Jul; 120(7):416-9. PubMed ID: 22441720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19.
    Covino M; De Matteis G; Burzo ML; Santoro M; Fuorlo M; Sabia L; Sandroni C; Gasbarrini A; Franceschi F; Gambassi G;
    Intern Med J; 2020 Dec; 50(12):1483-1491. PubMed ID: 33022124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.